Northern Trust
VERV

Northern Trust’s Verve Therapeutics VERV Stock Holding History

Northern Trust’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-588,830
Closed -$6.61M – 4543
2025
Q2 		$6.61M Sell
588,830
-32,472
-5% -$185K ﹤0.01% 2312
2025
Q1 		$2.84M Sell
621,302
-29,260
-4% -$196K ﹤0.01% 2737
2024
Q4 		$3.67M Buy
650,562
+73,295
+13% +$413K ﹤0.01% 2694
2024
Q3 		$2.79M Buy
577,267
+5,044
+0.9% +$29.3K ﹤0.01% 2792
2024
Q2 		$2.79M Sell
572,223
-8,559
-1% -$53.8K ﹤0.01% 2722
2024
Q1 		$7.71M Buy
580,782
+87,492
+18% +$1.16M ﹤0.01% 2210
2023
Q4 		$6.88M Buy
493,290
+26,968
+6% +$334K ﹤0.01% 2315
2023
Q3 		$6.18M Buy
466,322
+8,084
+2% +$130K ﹤0.01% 2313
2023
Q2 		$8.59M Buy
458,238
+54,675
+14% +$911K ﹤0.01% 2172
2023
Q1 		$5.82M Buy
403,563
+3,700
+0.9% +$72.5K ﹤0.01% 2366
2022
Q4 		$7.74M Buy
399,863
+10,947
+3% +$290K ﹤0.01% 2184
2022
Q3 		$13.4M Buy
388,916
+108,001
+38% +$3.45M ﹤0.01% 1777
2022
Q2 		$4.29M Buy
280,915
+1,416
+0.5% +$21.9K ﹤0.01% 2614
2022
Q1 		$6.38M Buy
279,499
+134,914
+93% +$3.86M ﹤0.01% 2434
2021
Q4 		$5.33M Buy
144,585
+4,494
+3% +$189K ﹤0.01% 2637
2021
Q3 		$6.58M Buy
+140,091
New +$8.24M ﹤0.01% 2562

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Northern Trust's VERV Position: Q3 2025 in Review

Northern Trust sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 588,830 shares — an estimated $6.61M sold.

Northern Trust first reported a position in VERV in Q3 2021 and held it in 16 quarters. The position peaked at $13.4M in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Northern Trust reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Northern Trust sold 588,830 Verve Therapeutics shares in Q3 2025, an estimated $6.61M.
  • Northern Trust first reported a position in Verve Therapeutics in Q3 2021 and held it in 16 quarters.
  • Northern Trust's Verve Therapeutics position peaked at $13.4M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Northern Trust's 13F filing for Q3 2025, filed 14 Nov 2025.